Terminated NA INTERVENTIONAL 2-arm NCT02308865

Early Palliative Care in Metastatic Lung Cancer in Northern France (IMPAQ)

Impact of Early Palliative Care on Quality of Life and Survival of Patients With Non-small-cell Metastatic Lung Cancer in Northern France

Sponsor: Novartis

Conditions Lung Cancer Metastatic

Interventions multi disciplinary palliative care monthly consultations

Updated 10 times since 2017 Last updated: Jul 9, 2019 Started: Oct 17, 2014 Primary completion: Feb 23, 2018 Completion: Feb 23, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

sponsor decision

Other terminated trials from Novartis

See all terminations from Novartis

Listed as NCT02308865, this NA trial focuses on Lung Cancer Metastatic and remains terminated or withdrawn. Sponsored by Novartis, it has been updated 10 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Terminated NA
Jul 2024 — Sep 2024 [monthly]

Terminated NA
Nov 2021 — Jul 2024 [monthly]

Terminated NA
Jan 2021 — Nov 2021 [monthly]

Terminated NA
Aug 2019 — Jan 2021 [monthly]

Terminated NA

Status: Recruiting → Terminated

▶ Show 5 earlier versions

Dec 2018 — Aug 2019 [monthly]

Recruiting NA
Jul 2018 — Dec 2018 [monthly]

Recruiting NA
Jun 2018 — Jul 2018 [monthly]

Recruiting NA
Jun 2017 — Jun 2018 [monthly]

Recruiting NA
Jan 2017 — Jun 2017 [monthly]

Recruiting NA

First recorded

Oct 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis
Santelys Association
University Hospital, Lille

Data source: University Hospital, Lille

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lille, France